In the course of combating new coronavirus pneumonia, how to quickly screen suspect patients and confirmed patients is an important process. Whether accurate and rapid determination of infected patients will affect the outcome of the epidemic. 2 Yue 10 evening,





Shenzhen University announced the successful development of new crown new virus chemiluminescence detection kit, the fastest 22 minutes a result, the experimental accuracy rate of 96% or more.

According to domestic media reports, this new kit was jointly developed by Shenzhen University and Shenzhen Third People's Hospital and Shenzhen Tianshen Medical Devices Co., Ltd.,





A full name is a single person 2019 new coronavirus IgM and IgG antibody chemiluminescence detection kit Compared with the current method of collecting upper respiratory tract samples ( predominantly throat swabs ) commonly used for nucleic acid detection, the new kit mainly verifies the samples' antibodies rather than nucleic acids.









Antibody samples mainly come from serum or plasma samples. The latter is not only convenient to collect but also generally has low toxic or virus-free blood samples, which can greatly reduce the risk of infection for medical staff and eliminate the need for complicated processing procedures during laboratory tests. Reduce detection time and improve detection efficiency.





According to Shenzhen University, single-person 2019 new coronavirus IgM and IgG antibody chemiluminescence detection kits are the first to be successfully developed in the world, and the results can be produced in as fast as 22 minutes.





As for the success rate of the test, the deep single-person 2019 new coronavirus IgM and IgG antibody chemiluminescence detection kit has completed 30 patients with new coronavirus pneumonia in Shenzhen Third People's Hospital ( National Infectious Disease Clinical Research Center ).





Detecting a blood sample, the initial clinical trial results show fever 7-14 days patient serum/plasma samples IgM clinical coincidence rate of 96.6% (29/30), IgG clinical coincidence rate of 96.6% (29/30).





At present, the research institute of the Shenzhen University team is collecting more clinical samples for large-scale verification, and the new kit developed is applying for the green channel and applying for CFDA certificate.



